Inogen Inc ( (INGN) ) has released its Q1 earnings. Here is a breakdown of the information Inogen Inc presented to its investors.
Inogen, Inc. is a global medical technology company specializing in innovative respiratory products designed for homecare settings, supporting patients with chronic respiratory conditions. In its first quarter of 2025, Inogen reported a revenue increase to $82.3 million, marking a 5.5% rise from the previous year, driven by strong demand from international and domestic business-to-business customers. However, this was partially offset by a decline in direct-to-consumer and rental revenues.
The company achieved a gross margin of 44.2%, slightly up from the previous year, and reduced its operating expenses by 13.1% to $44 million, primarily due to lower consulting expenses. Inogen reported a GAAP net loss of $6.2 million, a significant improvement from the $14.6 million loss in the prior year. Adjusted EBITDA turned positive at $0.04 million, compared to a negative $7.6 million in the previous year, highlighting improved financial performance.
Inogen’s cash position remains strong with $122.5 million in cash and no debt. The company anticipates continued revenue growth, projecting full-year 2025 revenue between $352 million and $355 million, with expectations to approach adjusted EBITDA breakeven. For the second quarter of 2025, Inogen forecasts revenue between $89 million and $91 million, reflecting modest growth.
Looking forward, Inogen’s management remains committed to enhancing commercial and operational execution to drive sustainable growth and profitability, aiming to create value for stakeholders while navigating market challenges.